Inflammation and cancer: back to Virchow?

PubWeight™: 27.40‹?› | Rank: Top 0.01% | All-Time Top 10000

🔗 View Article (PMID 11229684)

Published in Lancet on February 17, 2001

Authors

F Balkwill1, A Mantovani

Author Affiliations

1: ICRF Translational Oncology Laboratory, St Bartholomew's and Royal London School of Medicine and Dentistry, UK. f.balkwill@icrf.icnet.uk

Associated clinical trials:

Transcriptomal and Molecular Characterization of Tumor Associated Monocytes/Macrophages in Human Cancers | NCT00979277

The Role of the Muscle-nervous System Interface in Cancer Cachexia (NUMANCAN) | NCT03477721

Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy | NCT04425512

Articles citing this

(truncated to the top 100)

Inflammation and cancer. Nature (2002) 53.78

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09

Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41

A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54

Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37

Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (2012) 7.54

Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31

Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27

Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98

The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66

NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61

Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39

Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29

The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27

The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20

Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 4.15

NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10

Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A (2006) 4.08

A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell (2010) 4.02

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 3.91

NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86

miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med (2011) 3.78

Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76

Prostaglandins and cancer. Gut (2005) 3.44

Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A (2011) 3.42

Role of chemokines in tumor growth. Cancer Lett (2007) 3.36

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12

Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer (2007) 3.12

Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99

Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2005) 2.87

The microbiome and cancer. Nat Rev Cancer (2013) 2.86

CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81

Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature (2010) 2.79

Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62

Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51

A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health (2007) 2.50

The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol (2008) 2.46

Hashimoto's thyroiditis pathology and risk for thyroid cancer. Thyroid (2014) 2.39

Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut (2011) 2.38

Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg (2008) 2.38

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36

CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30

Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg (2007) 2.28

Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem Res Toxicol (2011) 2.24

Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19

History of the Baylor Charles A. Sammons Cancer Center. Proc (Bayl Univ Med Cent) (2003) 2.15

IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14

Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13

Why cancer and inflammation? Yale J Biol Med (2006) 2.13

High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer (2010) 2.11

Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol (2011) 2.10

Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09

A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer (2010) 2.08

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06

Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol (2006) 2.06

Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05

CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer (2010) 2.03

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest (2010) 2.02

Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing (2005) 1.99

Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med (2006) 1.98

Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer (2004) 1.98

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97

Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96

Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96

Apoptosis, stem cells, and tissue regeneration. Sci Signal (2010) 1.95

Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95

Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg (2010) 1.95

Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95

Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg (2006) 1.93

Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol (2011) 1.92

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91

Cancer-related inflammation. J Clin Immunol (2012) 1.91

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90

Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res (2002) 1.90

Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity (2014) 1.87

MYC regulates the antitumor immune response through CD47 and PD-L1. Science (2016) 1.87

Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87

Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood (2013) 1.85

An innate immune response of blood cells to tumors and tissue damage in Drosophila. Dis Model Mech (2008) 1.84

Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84

Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol (2009) 1.83

Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets (2007) 1.82

Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal (2011) 1.82

Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A (2009) 1.81

IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res (2008) 1.80

CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer (2009) 1.79

Inflammation: a driving force speeds cancer metastasis. Cell Cycle (2009) 1.78

Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest (2009) 1.78

The field of tissue injury in the lung and airway. Cancer Prev Res (Phila) (2008) 1.77

Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol (2008) 1.76

An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer (2006) 1.75

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74

The role of herbs and spices in cancer prevention. J Nutr Biochem (2008) 1.73

The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer (2010) 1.73

Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer (2005) 1.71

Articles by these authors

(truncated to the top 100)

Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56

Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31

Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol (1987) 4.75

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 4.53

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 4.19

Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood (1992) 4.11

Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol (2000) 4.07

The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med (1998) 3.70

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 3.62

Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem (1999) 3.53

Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol (1994) 3.31

IL-1 stimulates IL-6 production in endothelial cells. J Immunol (1989) 2.85

Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol (1998) 2.84

Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol (1998) 2.70

Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A (1993) 2.67

Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today (1989) 2.60

Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med (1990) 2.40

Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med (1997) 2.37

Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature (1989) 2.25

PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation (2000) 2.19

Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol (2000) 2.17

A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol (1997) 2.15

Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med (1992) 2.15

Prostacyclin synthesis induced in vascular cells by interleukin-1. Science (1985) 2.13

Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol (1990) 2.10

Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10

Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol (1995) 2.06

Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol (1997) 2.02

Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol (2000) 2.01

Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. J Immunol (1984) 2.01

Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 2.01

Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med (1997) 1.97

Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem (1997) 1.97

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax (2001) 1.94

Molecular mechanisms of blood vessel formation. Trends Biochem Sci (1997) 1.93

The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest (1995) 1.91

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90

Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene (2010) 1.88

Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer (1979) 1.84

Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83

The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today (1994) 1.83

Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80

Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest (1985) 1.79

Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci U S A (1994) 1.78

Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res (1990) 1.77

Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med (2001) 1.73

Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70

Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol (2000) 1.66

Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem (1992) 1.66

Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood (1994) 1.64

Monokine production by microglial cell clones. Eur J Immunol (1989) 1.64

Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells. J Exp Med (1997) 1.63

IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol (1998) 1.63

The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev (2000) 1.61

Intraoperative ultrasound during thoracoscopic procedures for solitary pulmonary nodules. Ann Thorac Surg (1999) 1.61

Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med (1998) 1.58

The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood (2000) 1.58

Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57

Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57

Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb (1991) 1.57

Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther (2010) 1.54

Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol (1988) 1.53

The role of chemokines in the regulation of dendritic cell trafficking. J Leukoc Biol (1999) 1.53

A risk factor for female fertility and pregnancy: celiac disease. Gynecol Endocrinol (2000) 1.52

Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol (1992) 1.51

Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J Exp Med (1991) 1.51

The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med (1997) 1.51

Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol (1994) 1.50

Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol (1999) 1.50

Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun (1990) 1.48

IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology (1990) 1.47

Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol (2001) 1.47

Natural cytotoxicity of mouse monocytes and macrophages. J Immunol (1979) 1.43

Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer (1980) 1.43

Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J Immunol (1994) 1.42

The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood (1998) 1.42

Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41

Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol (1991) 1.41

Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood (1998) 1.39

Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest (2000) 1.38

PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum (2001) 1.37

Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol (1998) 1.37

Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol (1986) 1.37

Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor. Immunology (1987) 1.37

Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. J Immunol (1999) 1.37

Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood (1996) 1.37

Molecules involved in the adhesion and cytotoxicity of activated monocytes on endothelial cells. J Immunol (1992) 1.36

Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses. Blood (1998) 1.34

Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol (1992) 1.33

Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur J Immunol (2001) 1.33

Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med (1995) 1.31

In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest (1991) 1.31

Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood (1988) 1.30

Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br J Cancer (1980) 1.29

The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol (1991) 1.28

Murine endothelioma cell lines transformed by polyoma middle T oncogene as target for and producers of cytokines. J Immunol (1991) 1.27

Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med (1991) 1.27

The European study of assisted reproduction families: family functioning and child development. Hum Reprod (1996) 1.25

Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem (1997) 1.25